SG11201901251SA - Aminopyrimidines as alk inhibitors - Google Patents
Aminopyrimidines as alk inhibitorsInfo
- Publication number
- SG11201901251SA SG11201901251SA SG11201901251SA SG11201901251SA SG11201901251SA SG 11201901251S A SG11201901251S A SG 11201901251SA SG 11201901251S A SG11201901251S A SG 11201901251SA SG 11201901251S A SG11201901251S A SG 11201901251SA SG 11201901251S A SG11201901251S A SG 11201901251SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- co7d
- english
- august
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
NO H Kr NH 0-R6 R 7 R2a Rib N R2b R3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIP0 I PCT o mono °nolo olo Ho Ho Imo (10) International Publication Number WO 2018/044767 A2 (51) International Patent Classification: CO7D 405/14 (2006.01) A61P 35/00 CO7D 401/12 (2006.01) A61P 29/00 A61K 31/506 (2006.01) A61P 37/00 (21) International Application Number: PCT/US2017/048845 (22) International Filing Date: 28 August 2017 (28.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/380,818 29 August 2016 (29.08.2016) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Office Of Technology Trans- fer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US). (72) Inventors: WANG, Shaomeng; 3336 Stirling Ct., Superi- or Township, MI 49198 (US). CHEN, Jianyong; 2659 Ar- rowwood Trial, Ann Arbor, MI 48105 (US). (74) Agent: NAPOLI, James, J.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) (2006.01) (2006.01) (2006.01) W O 20 18/0 447 67 A2 (54) Title: AMINOPYRIMIDINES AS ALK INHIBITORS (57) : The present disclosure provides compounds represented by For- mula (I): and the pharmaceutically acceptable salts, hydrates, and solvates there- 5 of, wherein R ia , R ib , R , R , R, R, R 2a 2b 3 4 5 , R 6 , and R 7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formu- la (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380818P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/048845 WO2018044767A2 (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901251SA true SG11201901251SA (en) | 2019-03-28 |
Family
ID=59846649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901251SA SG11201901251SA (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
| SG10201914030UA SG10201914030UA (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201914030UA SG10201914030UA (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10709705B2 (en) |
| EP (2) | EP3504203B1 (en) |
| JP (2) | JP7094566B2 (en) |
| KR (1) | KR102530871B1 (en) |
| CN (2) | CN109715620B (en) |
| AU (2) | AU2017319135B2 (en) |
| BR (1) | BR112019003897A2 (en) |
| CA (1) | CA3033223A1 (en) |
| IL (1) | IL264638B (en) |
| MX (2) | MX2019002393A (en) |
| NZ (1) | NZ751713A (en) |
| SG (2) | SG11201901251SA (en) |
| WO (1) | WO2018044767A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11478477B2 (en) | 2018-07-31 | 2022-10-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor |
| CN111171033B (en) * | 2018-11-09 | 2021-11-02 | 天津大学 | Pyrimidine derivative and synthesis method and application thereof |
| MX2021009863A (en) | 2019-03-21 | 2021-11-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer. |
| CN110143947B (en) * | 2019-05-29 | 2021-10-15 | 华东师范大学 | Preparation method of ceritinib analogue |
| US20220117964A1 (en) * | 2019-06-25 | 2022-04-21 | Ascentage Pharma (Suzhu) Co., Ltd. | Combination of fak inhibitor and btk inhibitor for treating a disease |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230381176A1 (en) * | 2020-09-25 | 2023-11-30 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical composition and use thereof for treatment of cancer |
| WO2022222932A1 (en) * | 2021-04-19 | 2022-10-27 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| ES2424881T3 (en) | 2003-08-15 | 2013-10-09 | Novartis Ag | 2,4-Di (phenylamino) -pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| CN100584832C (en) * | 2003-09-18 | 2010-01-27 | 诺瓦提斯公司 | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| RS52545B (en) * | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitors of iap |
| ES2524009T3 (en) | 2006-12-08 | 2014-12-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US8592432B2 (en) | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2627179A4 (en) | 2010-10-14 | 2014-04-02 | Ariad Pharma Inc | Methods for inhibiting cell proliferation in egfr-driven cancers |
| EP2670401B1 (en) * | 2011-02-02 | 2015-06-10 | Novartis AG | Methods of using alk inhibitors |
| CN104672214B (en) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | Compound and its preparation and purposes with ALK inhibitory activity |
| KR101656382B1 (en) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | pyrimidine-2,4-diamine derivatives and pharmaceutical composition for anti cancer containing the same as an active ingredient |
-
2017
- 2017-08-28 BR BR112019003897-3A patent/BR112019003897A2/en unknown
- 2017-08-28 CN CN201780057518.0A patent/CN109715620B/en active Active
- 2017-08-28 CA CA3033223A patent/CA3033223A1/en active Pending
- 2017-08-28 MX MX2019002393A patent/MX2019002393A/en unknown
- 2017-08-28 WO PCT/US2017/048845 patent/WO2018044767A2/en unknown
- 2017-08-28 AU AU2017319135A patent/AU2017319135B2/en active Active
- 2017-08-28 KR KR1020197007075A patent/KR102530871B1/en active IP Right Grant
- 2017-08-28 JP JP2019511664A patent/JP7094566B2/en active Active
- 2017-08-28 EP EP17764949.8A patent/EP3504203B1/en active Active
- 2017-08-28 SG SG11201901251SA patent/SG11201901251SA/en unknown
- 2017-08-28 EP EP21212760.9A patent/EP4001273A3/en not_active Withdrawn
- 2017-08-28 NZ NZ751713A patent/NZ751713A/en unknown
- 2017-08-28 CN CN202210533398.XA patent/CN115043821A/en active Pending
- 2017-08-28 US US15/559,445 patent/US10709705B2/en active Active
- 2017-08-28 SG SG10201914030UA patent/SG10201914030UA/en unknown
-
2019
- 2019-02-04 IL IL264638A patent/IL264638B/en unknown
- 2019-02-27 MX MX2022000376A patent/MX2022000376A/en unknown
-
2020
- 2020-06-29 US US16/914,518 patent/US11110090B2/en active Active
-
2021
- 2021-05-14 AU AU2021203098A patent/AU2021203098B2/en active Active
-
2022
- 2022-06-15 JP JP2022096630A patent/JP2022120151A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190039760A (en) | 2019-04-15 |
| MX2022000376A (en) | 2022-02-10 |
| WO2018044767A3 (en) | 2018-04-12 |
| CA3033223A1 (en) | 2018-03-08 |
| IL264638B (en) | 2021-08-31 |
| AU2021203098A1 (en) | 2021-06-10 |
| NZ751713A (en) | 2022-07-01 |
| AU2021203098B2 (en) | 2023-05-25 |
| JP7094566B2 (en) | 2022-07-04 |
| WO2018044767A2 (en) | 2018-03-08 |
| US20190175595A1 (en) | 2019-06-13 |
| AU2017319135B2 (en) | 2021-03-18 |
| EP3504203B1 (en) | 2022-09-28 |
| MX2019002393A (en) | 2019-07-08 |
| EP3504203A2 (en) | 2019-07-03 |
| US20200330464A1 (en) | 2020-10-22 |
| SG10201914030UA (en) | 2020-03-30 |
| CN115043821A (en) | 2022-09-13 |
| US11110090B2 (en) | 2021-09-07 |
| KR102530871B1 (en) | 2023-05-09 |
| CN109715620A (en) | 2019-05-03 |
| CN109715620B (en) | 2022-05-06 |
| JP2022120151A (en) | 2022-08-17 |
| BR112019003897A2 (en) | 2019-05-21 |
| JP2019528307A (en) | 2019-10-10 |
| US10709705B2 (en) | 2020-07-14 |
| EP4001273A2 (en) | 2022-05-25 |
| AU2017319135A1 (en) | 2019-04-04 |
| EP4001273A3 (en) | 2022-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201908542QA (en) | Gip receptor activating peptide | |
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201907744QA (en) | Replacement of cytotoxic preconditioning before cellular immunotherapy | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto |